Krystal Biotech (KRYS) Free Cash Flow (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Free Cash Flow data on file, last reported at $73.2 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 195.72% year-over-year to $73.2 million; the trailing twelve-month figure through Mar 2026 stood at $246.3 million (up 96.92% YoY), and the FY2025 full-year result was $197.8 million, up 72.11% from the prior year.
• Free Cash Flow declined to $73.2 million in Q1 2026, from $75.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $75.1 million in Q4 2025 to a low of -$65.3 million in Q2 2022.
• A 5-year average of $10.2 million and a median of $2.5 million in 2022 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow tumbled 1665.39% in 2022 and jumped 601.95% in 2025, its largest moves.
• Tracing KRYS's Free Cash Flow over 5 years: stood at -$37.2 million in 2022, then surged by 57.59% to -$15.8 million in 2023, then jumped by 402.69% to $47.8 million in 2024, then jumped by 57.09% to $75.1 million in 2025, then retreated by 2.44% to $73.2 million in 2026.
• Business Quant data shows KRYS's Free Cash Flow at $73.2 million in Q1 2026, $75.1 million in Q4 2025, and $40.4 million in Q3 2025.